PMC5222945_01
An abdominal contrast-enhanced computed tomography (CT) scan showed a solitary mass in the liver (a). The size was 16 x 29 mm. In the arterial phase (b), the tumor was slightly enhanced. In the portal and delayed phase (c, d), the tumor staining was sustained.
gr1.jpg
PMC5222945_01_gr1.jpg
fig0005
On contrasted CT, the tumor was slightly enhanced at the early phase, and tumor staining was sustained at the delayed phase (Fig. 1a-d).
Magnetic resonance imaging (MRI) showed a solitary mass in the liver. (a) The tumor was weakly enhanced in the early phase. (b) In the late and hepatobiliary phase (c, d), the tumor gradually revealed as a hypo intense area.
gr2.jpg
PMC5222945_01_gr2.jpg
fig0010
MRI showed that the tumor was weakly enhanced at the early phase, and revealed hypo intense areas at both late and hepatobiliary phases (Fig. 2a-d).
The specimen shows that the tumor was a whitish solid with an irregular margin.
gr3.jpg
PMC5222945_01_gr3.jpg
fig0015
The specimen shows that the tumor was a whitish solid with an irregular margin (Fig. 3).
Immunohistochemistry demonstrated that the tumor was positive for CD20, CD30, and CD79a, but negative for CD10 and CD15.
gr4.jpg
PMC5222945_01_gr4.jpg
fig0020
On immunohistochemical analysis, CD20, CD30, and CD79a were positive, but CD10 and CD15 were negative (Fig. 4).